MD Anderson, through its Shared Governance Committee, is moving away from an “autocratic” structure, said Julie Izzo, chair of the Faculty Senate and an associate professor in Translational Molecular Pathology at MD Anderson Cancer Center.
If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly counters the wisdom of the U.S. Congress, who less than a year ago overwhelmingly passed the 21st Century Cures Act.
After seven months of continuing resolutions, Congress voted to pass a $1.1 trillion spending bill covering the remainder of the fiscal year 2017—approving a $2 billion increase for NIH.
Two weeks ago, Vivian Lee and David Pershing attempted to oust Mary Beckerle from her job at Huntsman Cancer Institute.
FDA granted accelerated approval to Genentech's Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
The American Society for Radiation Oncology issued a clinical guideline for the management of oropharyngeal cancer.
Genetic testing of tumor and blood fluid samples from people with and without one of the most aggressive forms of skin cancer has shown that two new blood tests can reliably detect previously unidentifiable forms of the disease.
Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released March 21 by the Journal of the American Medical Association.
Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for Cancer Research.
